Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/16/2025 | $44.00 | Buy | Truist |
| 8/6/2025 | $31.00 | Buy | H.C. Wainwright |
| 4/8/2025 | Mkt Outperform | Citizens JMP | |
| 7/2/2024 | Buy | TD Cowen | |
| 7/2/2024 | $35.00 | Buy | Jefferies |
| 7/2/2024 | $35.00 | Buy | Stifel |
4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
BOSTON and SAN DIEGO, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (NASDAQ:RAPP) ("Rapport" or the "Company"), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced that management plans to participate in the following upcoming investor conference. TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit (virtual) – fireside chat on Wednesday, September 17, 2025, at 11:20 am ET. Interested parties may access a live and archived webcast of the fireside chat on the "Investors" section of the company's website at:
BOSTON and SAN DIEGO, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (NASDAQ:RAPP) ("Rapport" or the "Company"), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced the pricing of an underwritten public offering of 9,615,385 shares of its common stock at a public offering price of $26.00 per share. All of the shares in the offering are being sold by Rapport. In addition, Rapport has granted the underwriters a 30-day option to purchase up to an additional 1,442,307 shares of its common stock at the public offering price, less underwritin
BOSTON and SAN DIEGO, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (NASDAQ:RAPP) ("Rapport" or the "Company"), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced that it has commenced an underwritten public offering of $250.0 million of shares of its common stock. All of the shares in the proposed offering are being offered by Rapport. In addition, Rapport intends to grant the underwriters a 30-day option to purchase up to an additional $37.5 million of shares of its common stock at the public offering price, less underwriting discou
Truist initiated coverage of Rapport Therapeutics with a rating of Buy and set a new price target of $44.00
H.C. Wainwright initiated coverage of Rapport Therapeutics with a rating of Buy and set a new price target of $31.00
Citizens JMP initiated coverage of Rapport Therapeutics with a rating of Mkt Outperform
SCHEDULE 13D/A - Rapport Therapeutics, Inc. (0002012593) (Subject)
144 - Rapport Therapeutics, Inc. (0002012593) (Subject)
144 - Rapport Therapeutics, Inc. (0002012593) (Subject)
4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
Alto Neuroscience, Inc. ("Alto") (NYSE:ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the appointment of Raymond Sanchez, M.D., to its Board of Directors, effective August 12, 2025. Dr. Sanchez is a highly accomplished executive with a strong background in medicine and over 20 years of strategic experience in the life sciences industries. "We are delighted to welcome Ray to our Board of Directors as we continue advancing multiple clinical-stage precision psychiatry programs," said Amit Etkin, M.D., Ph.D., founder and chief executive officer of Alto Neuroscience. "Ray brings an impress
Results of positron emission tomography (PET) trial and second multiple ascending dose (MAD-2) trial support RAP-219's transformative potential for epilepsy and other central nervous system (CNS) disorders Continued momentum in the Phase 2a trial of RAP-219 in patients with refractory focal epilepsy, with topline results expected in the third quarter of 2025Expect to initiate a Phase 2a trial in patients with bipolar mania in the third quarter of 2025, with topline results expected in the first half of 2027 Appointed recognized translational and clinical drug development leader, Jeffrey Sevigny, M.D., as chief medical officer Ended the year with $305.3 million in cash, cash equivalents, an
BOSTON and SAN DIEGO, March 03, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (NASDAQ:RAPP), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients suffering from central nervous system (CNS) disorders, today announced the appointment of Dr. Jeffrey Sevigny as chief medical officer (CMO), effective immediately. A physician-scientist with more than 15 years of leadership in translational and clinical drug development, Dr. Sevigny has spearheaded groundbreaking research across neuroscience and rare diseases. His experience spans the full spectrum of development, from discovery to late-stage clinical trials an
Trial met primary long episode endpoints with high statistical significance, and RAP-219 was generally well toleratedPatients achieved 77.8% reduction in clinical seizures (p=0.01), with 24% achieving seizure freedom for the 8-week treatment period (p<0.0001)Data support advancement of RAP-219 into Phase 3 registrational trialsCompany to host a conference call today at 8:00 a.m. ET BOSTON and SAN DIEGO, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (NASDAQ:RAPP) ("Rapport" or the "Company"), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today
BOSTON and SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (NASDAQ:RAPP) ("Rapport" or the "Company"), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced that it will host a conference call and live webcast at 8:00 am ET on September 8, 2025, to report topline results for the Phase 2a trial of RAP-219 in patients with drug-resistant focal onset seizures. Individuals interested in listening to the live conference call may do so through this webcast link or by dialing (800) 715-9871 in the U.S. or (646) 307-1963 for other
SC 13G - Rapport Therapeutics, Inc. (0002012593) (Subject)
SC 13G/A - Rapport Therapeutics, Inc. (0002012593) (Subject)
SC 13G - Rapport Therapeutics, Inc. (0002012593) (Subject)